학술논문
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Document Type
Article
Author
Johnson, Isla M.; Karrar, Omer; Rana, Masooma; Iftikhar, Moazah; Chen, Sunny; McCullough, Kristen; Saliba, Antoine N.; Al‐Kali, Aref; Alkhateeb, Hassan; Begna, Kebede; Litzow, Mark; Hogan, William J.; Shah, Mithun; Patnaik, Mrinal M.; Pardanani, Animesh; Hermann, Joerg; Tefferi, Ayalew; Gangat, Naseema
Source
Subject
*ACUTE myeloid leukemia
*NON-ST elevated myocardial infarction
*VENETOCLAX
*PERICARDITIS
*MYOCARDIAL infarction
*CARDIOVASCULAR diseases risk factors
*
*
*
*
*
Language
ISSN
0007-1048
Abstract
Summary: Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A‐mutated cases less likely (p < 0.01) to be affected. Treatment‐emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination. [ABSTRACT FROM AUTHOR]